11.16.2026
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Advancing Retinal Disease Pipeline
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with additional potential milestone payments of up to approximately $1.1 billion, expanding its ophthalmology pipeline with an investigational therapy for retinal diseases. The acquisition would add OLN324, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), to Johnson & Johnson's portfolio.